Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

AI Rating

Rating methodology
Latest close (chg%)26.62+0.15%
Buy price
26.25
Target price29.00
Sell price25.20
P/E TTM19.45
P/E18.50
Confidence72%
Risk score60/100
AI Summary
Pfizer is fundamentally undervalued with oversold technicals near critical support, trading below industry average P/E with 6.3% dividend yield providing downside protection. Strong oncology pipeline with multiple near-term catalysts including PADCEV+Keytruda results offering 9-13% upside potential. Patent cliff risks for Eliquis are already priced in and don't impact until late 2026/early 2027.

Alpha Score

0-10
  • Trend（Score 4/10）

    Pfizer exhibits weak technical characteristics with price below key moving averages and negative momentum, but approaching oversold conditions with strong historical support around current levels.

  • Valuation（Score 7/10）

    Pfizer appears slightly undervalued with PE ratios below industry average and reasonable valuation metrics supporting potential upside to base case targets of $29-31.

  • Financial strength（Score 7/10）
    Solid financial condition with robust profitability metrics and efficient capital allocation, though specific liquidity and debt details are limited.
  • Profitability（Score 8/10）
    Strong profitability with high gross margins and solid returns, though net margins compressed slightly due to COVID-19 revenue transition.
  • Sentiment（Score 7/10）
    Pfizer demonstrates strong momentum with 11% YTD stock rally driven by oncology breakthroughs and attractive 6.3% dividend yield, though facing challenges from declining COVID sales and patent cliffs.
Latest price
$26.62+0.15%
Market cap151.41B
P/E TTM19.45
P/E18.50
Volume30.79M
Turnover821.93M